BRAF and non-small cell lung carcinoma: Another ongoing phase II clinical study (ENCO-BRAF trial; NCT04526782, Table 1) is evaluating the efficacy of the encorafenib–binimetinib combination in advanced BRAFV600E-mutant NSCLC patients.